OFFICIAL PRESS RELEASE
Revelation Pharma Corporation
Revelation Pharma Corp Acquires Innovation Compounding, Inc
This marks the 6th acquisition for the Revelation Platform
TAMPA, Fla., Osceola Capital (“Osceola”), a lower middle-market private equity firm, announced today the sixth addition to the Revelation Pharma Corporation (“Revelation”) platform. Revelation purchased Innovation Compounding, Inc (“Innovation”), a 503A compounding pharmacy that offers sterile and non-sterile compounded medications to patients in 49 states.
The acquisition of Innovation represents Revelation’s continued desire to acquire and grow a national partnership of 503A and 503B compounding pharmacies. The one-size fits all formula of mass-produced medications does not fit the customized needs of every patient. Compounding pharmacies prepare high quality custom prescriptions to address the exact clinical need and often improve quality of life for patients.
The corporate team for Revelation is led by Richard Case, a healthcare M&A industry veteran, with significant experience in acquisitions of lower middle-market healthcare businesses that operate in highly regulated industries. Serving as Chairman of the Board, Jake Beckel, a pharmacist, has deep experience in the compounding space. He most recently served as founder and CEO of AnazaoHealth Corporation, a leading compounding pharmacy which successfully completed 13 acquisitions and ultimately was acquired by Fagron, the world’s largest publicly traded compounding company. Michelle Case, who has successfully directed 20+ grassroots start-ups, and also successfully launched an IPO, serves as Chief Operations Officer.
Innovation’s leadership will also participate in the growth of Revelation’s network. Innovation’s CEO and President, Shawn Hodges will serve as Chief Business Development Officer for Revelation. Mitchell Bell who served as Vice President of Operations at Innovation, will serve as Sr. VP of 503A Pharmacies for Revelation.
“Innovation is regarded as a reputable compounding pharmacy that has been able to provide high-quality compounded therapies to hundreds of thousands of patients over the past 15 years. We’re excited that Shawn, Mitchell, and the Innovation Compounding Team is joining our rapidly growing network, that will help contribute to our desire to offer best-in-class therapies and services to patients and their providers,” said Richard Case.
“We’re elated to join the Revelation network”, Shawn Hodges said. “We’ve been approached by numerous firms wanting to acquire Innovation, but we selected Revelation because they are knowledgeable about the compounding market, they appreciate the need to invest into quality, and they believe that patients deserve the right to access compounded therapies. The future is very bright by joining the Revelation team.”
The pipeline for pharmacy partnerships is rapidly increasing. Pharmacy owners are recognizing the need for support to respond to the changes in the regulatory landscape, and yet the pharmacy owner still seeks to practice the art of pharmacy compounding and serve their patient’s unique and individual needs. Revelation’s long-term goal is the become the leader in the compounding space, by supporting and acquiring pharmacies while developing a sophisticated quality assurance among all pharmacies in the network.
About Osceola Capital Management
Osceola Capital is a Tampa-based private equity firm that invests in lower middle-market services companies, typically with EBITDA of $2 million to $10 million. Osceola has extensive experience partnering with management teams to execute buy-and-build strategies and drive long-term value creation. The Revelation Strategy Team includes Ben Moe, Patrick Watkins, and Jordyn Steinkritz.
To learn more, visit www.osceola.com.
About Revelation Pharma Corporation
Revelation Pharma is a national network of 503A and 503B compounding pharmacies providing innovative and quality pharmaceutical products and services through “industry best” patient care and solutions for customers. Compounding pharmacy will drastically change in the next five years. Revelation’s belief is that compounding pharmacies will need help and support to adjust to these changes in order to continue to serve the needs of the patient and their healthcare provider.
To learn more, visit www.revcustomrx.com.
About Innovation Compounding
Innovation Compounding is a 503A compounding-only, pharmacy that ships over 120,000 prescriptions annually to patients in 49 states. The pharmacy provides patient-specific sterile and non-sterile prescriptions for those patients that need custom medications. Innovation is a Pharmacy Compounding Accreditation Board (PCAB) accredited pharmacy and offers compounded products under a myriad of therapeutic lines. Some of which include, women’s health, men’s health, skin care, non-narcotic pain management, weight management, chronic disease states, animal health, allergy, and miscellaneous drug shortages.
CONNECT WITH US
6095 Pine Mountain Rd. NW,
Kennesaw, GA 30152
(800) 547-1399 Ph.
(866) 635-2329 Fax
9:00 a.m.-6:00 p.m. M-Th
9:00 a.m.-5:00 p.m. Fri